REPLIGEN CORP Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
REPLIGEN CORP (RGEN) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price of $109.47 per share as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice · last filed 2026-07-29
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $109.47.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $109.15.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $107.80.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $105.26.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $109.47 10-Q · filed 2026-07-29 |
| 2026-03-31 | $109.15 10-Q · filed 2026-05-06 |
| 2025-12-31 | $107.80 10-K · filed 2026-02-26 |
| 2025-09-30 | $105.26 10-Q · filed 2025-11-04 |
| 2025-06-30 | $102.76 10-Q · filed 2025-08-07 |
| 2025-03-31 | $102.70 10-Q · filed 2025-04-29 |
| 2024-12-31 | $98.05 10-K · filed 2025-03-14 |
| 2024-09-30 | $92.66 10-Q · filed 2024-11-18 |
| 2024-06-30 | $91.51 10-Q/A · filed 2024-11-18 |
| 2024-03-31 | $92.21 10-Q/A · filed 2024-11-18 |
| 2023-12-31 | $85.49 10-K/A · filed 2024-11-18 |
| 2023-09-30 | $83.18 10-Q/A · filed 2024-11-18 |
| 2023-06-30 | $80.08 10-Q/A · filed 2024-11-18 |
| 2023-03-31 | $78.10 10-Q/A · filed 2024-11-18 |
| 2022-12-31 | $71.30 10-K · filed 2023-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |